CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ascent Therapeutics, Inc., a biopharmaceutical company developing a new class of lipidated peptides called Pepducins to target G-protein coupled receptors (GPCRs), today announced two additions to the Company’s senior management team with the appointment of John Tagliamonte as Vice President, Business Development and Michael Houston, Ph.D. as Vice President, Preclinical Chemistry and CMC. Mr. Tagliamonte most recently served as Vice President Business Development for ImmunoGen, Inc. and Dr. Houston was previously Vice President of Chemistry and Formulations at MDRNA, Inc.
